BRAF and melanoma: We therefore went on to screen the drug effect on a cohort of 30 patient-derived short-term cultures of melanoma cell lines carrying BRAFV600E/K, NRASQ61K/L/R, NF1null, RAC1P129S, RAF1 or BRAF fusion proteins, as well as other mutations identified by exome-capture sequencing (Table 1 and Supplementary Table 2).